@ARTICLE{Szczepanik_M.P._Evaluation_2020,
 author={Szczepanik, M.P. and Popiel, J. and Cekiera, A. and Pomorska-Handwerker, D. and Karaś-Tęcza, J. and Ściskalska, M. and Oczkowska, K. and Taube, M. and Olender, V. and Parys, P.},
 volume={vol. 23},
 number={No 2},
 journal={Polish Journal of Veterinary Sciences},
 pages={191-195},
 howpublished={online},
 year={2020},
 publisher={Polish Academy of Sciences Committee of Veterinary Sciences},
 publisher={University of Warmia and Mazury in Olsztyn},
 abstract={Atopic dermatitis (AD) is the most frequent allergic disease in dogs. AD can be treated using allergenspecific immunotherapy as well as symptomatic antipruritic treatment including the use of lokivetmab - caninized anti-interleukine-31 antibody. The aim of the study was to evaluate the effectiveness of lokivetmab over 12 weeks of treatment. Studies have been carried out in 89 dogs. In all affected animals, the severity of lesions was assessed using the CADESI 04 and the pruritus was assessed using the VAS. After the first dose of lokivetmab, both CADESI 04 and VAS statistical decreased by 4 weeks from 40.48 to 20.31, and from 7.42 to 2.48, respectively (p = 0.0000001) maintained significantly decresed values during the whole treatment period (CADESI 04 15.64, 15.07 after 8 and 12 weeks, respectively, PVAS 2.03, 1.95 after 8 and 12 weeks, respectively). Lokivetmab leads to a significant reduction of CADESI 04 and pruritus, within four weeks and maximum effect is achived after the second dose.},
 type={Article},
 title={Evaluation of the clinical efficiencyof lokivetmab in client privately ownedatopic dogs – multicenter study},
 URL={http://www.czasopisma.pan.pl/Content/116005/PDF/4.pdf},
 doi={10.24425/pjvs.2020.132765},
 keywords={atopic dermatitis, dog, lokivetmab},
}